IMP321: Phase IIb started

Prima began the European Phase IIb AIPAC trial of subcutaneous IMP321 on days 2 and 16 of each 4-week cycle plus IV paclitaxel on days 1, 8 and 15 vs. paclitaxel alone in about 211 patients. An open-label portion will determine the recommended dose of IMP321 and paclitaxel in about 15 patients. A double-blind portion will compare IMP321 plus paclitaxel at the recommended dose vs. paclitaxel alone in about 196 patients. After 6 cycles, patients will receive IMP321 or placebo every 4 weeks for 52 weeks. ...